Ionis Pharmaceuticals: Is the RNA specialist poised for a growth phase thanks to Tryngolza potential?
Reading Time: 3 minutes
Citi analyst Eric Joseph confirms a price target of Ionis Pharmaceuticals (IONS) of 100 USD and considers the recent price losses a clear overreaction. The drug Tryngolza exceeds expectations; the forecast for peak sales has been raised to over 1.8 billion euros. The transition to a fully commercial biotech company is supported by a pipeline with five upcoming Phase 3 data releases in 2026. Focus on RNA Technology and Commercial Transformation Ionis Pharmaceuticals (IONS) focuses on the development of RNA-based therapeutics, addressing complex...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
